Peptide

VK2735

Also known as

Viking VK2735 · VK-2735 · VKTX dual agonist · Viking GLP-1/GIP dual agonist · VENTURE VK2735 · VANQUISH VK2735 · Oral VK2735 / VK2735 tablet

Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.

What it is

Identity	Viking's experimental GLP-1/GIP peptide for weight management, developed as injections and tablets. The same molecule has different absorption by route; equal milligrams do not mean equal exposure.
Blinded trial accounts	Participants often do not know their dose or whether they received active drug. Their symptoms and weight changes cannot reveal the assigned treatment.

Notes

VK2735 is Viking’s experimental GLP-1/GIP peptide for weight management, developed as injections and tablets. Trial participants discuss quieter food cravings, smaller meals and weight loss, but also plateaus, fatigue and difficult side effects. Their blinded reports cannot reveal which dose—or even active drug—they received.

One peptide, two formulations. GLP-1 and GIP are gut-hormone signals involved in appetite and blood-sugar regulation. VK2735 activates both receptors. Injections and clinical tablets contain the same molecule, but absorption differs; equal milligrams do not mean equivalent exposure. Viking VK2735 pipeline overview (Official context · Accessed 2026-09-30)

Weekly SubQ: 7.5, 12.5 or 17.5 mg target-arm talk. SubQ means beneath the skin. Participants list these possible trial targets but often do not know their assignment. Another author describes a presumed increase to 7.5 mg at the eleventh injection. These are per-injection trial amounts discussed by users, not confirmed personal dose ladders. Anyone on the Vanquish 1 trial? (Community discussion · Accessed 2026-09-30) · 36 week shot (Community discussion · Accessed 2026-09-30) · Early participants? Just had my 11th injection and the increase to 7.5 (Community discussion · Accessed 2026-09-30)

A quiet first week or slower change also appears. One poster initially suspected placebo, then noticed less craving. Another approaching the ninth injection reported fullness and occasional nausea but under 10 lb lost. Blinding prevents calling a slow or absent response a confirmed VK2735 failure. Anyone on the Vanquish 1 trial? (Community discussion · Accessed 2026-09-30) · 4th Dose (Community discussion · Accessed 2026-09-30)

Source context — Viking VK2735 pipeline overview: Sponsor summary with commercial interest; headline tolerability language does not establish safety or approval.

Source context — Anyone on the Vanquish 1 trial? / Early participants? Just had my 11th injection and the increase to 7.5 / 4th Dose: Anonymous, self-identified blinded trial participants; allocation, amount and medical records are unverified. Selected public replies, not a representative sample.

Source context — 36 week shot: Anonymous, self-identified blinded trial participants; allocation, amount and medical records are unverified. Selected public replies, not a representative sample. Some replies concern stock speculation; no dose assignment is established by sensations.

What people notice

Food noise and portions	Participants describe less interest in sweets, earlier fullness and smaller meals. One fourth-dose account reports 13 lb lost alongside resumed exercise.
Plateaus and slower change	One week-36 poster reports 23% loss with six weeks at stable weight. Another nearing injection nine reports under 10 lb lost with fullness and nausea; these are different blinded experiences.

Notes

Less food noise and easier fullness. Participants describe losing interest in sweets or stopping halfway through old portions. A fourth-dose account reported 13 lb lost and fewer dessert thoughts, alongside resumed exercise. Anyone on the Vanquish 1 trial? (Community discussion · Accessed 2026-09-30) · 4th Dose (Community discussion · Accessed 2026-09-30)

Progress can slow without disappearing. At week 36, one poster reported 23% weight loss but six weeks of stable weight. Another described a month without scale loss followed by further progress. Those stories answer what a plateau feels like; they cannot forecast anyone else’s trajectory. 36 week shot (Community discussion · Accessed 2026-09-30)

Source context — Anyone on the Vanquish 1 trial? / 4th Dose: Anonymous, self-identified blinded trial participants; allocation, amount and medical records are unverified. Selected public replies, not a representative sample.

Doses people talk about

Weekly SubQ trial-arm talk	Participants list possible 7.5, 12.5 or 17.5 mg target arms; their assignment is often unknown. A presumed increase to 7.5 mg at injection eleven is not a confirmed personal dose ladder.
Oral accounts	A favorable oral-trial report gives no tablet strength or timing, so no dependable self-reported oral band emerges. Daily tablet and weekly injection milligrams are not interchangeable.
Separate Phase 2 context	Research arms used injections at 2.5, 5, 10 or 15 mg weekly, or oral tablets at 15, 30, 60, 90 or 120 mg daily for thirteen weeks. Those are supervised trial amounts, not verified forum assignments.

Notes

Oral: no dependable self-reported dose band here. An oral-trial commenter reports good tolerability and 22 lb lost without giving tablet strength or timing. Daily oral trial milligrams and weekly injection milligrams cannot be converted one-for-one; neither establishes the contents of a nonclinical product. Viking Therapeutics: oral-trial participant reply (Personal report · Accessed 2026-09-30)

Injectable Phase 2: 2.5, 5, 10 or 15 mg once weekly for 13 weeks. Viking reports up to 14.7% mean weight loss from baseline. Nausea, vomiting, constipation and diarrhea occurred, with a drug-related serious dehydration event. Group averages do not verify a forum user’s assignment. Viking VK2735 pipeline overview (Official context · Accessed 2026-09-30) · VENTURE weekly injection trial poster (Official context · Accessed 2026-09-30)

Oral Phase 2: 15, 30, 60, 90 or 120 mg daily for 13 weeks. Top-arm mean loss was 12.2%; vomiting occurred in 35% of the 90 and 120 mg groups, and 38% in the 120 mg group stopped treatment early. These are distinct trial outcomes, not community rates. Viking VENTURE-Oral results, August 2025 (Official context · Accessed 2026-09-30)

Source context — Anyone on the Vanquish 1 trial? / Early participants? Just had my 11th injection and the increase to 7.5: Anonymous, self-identified blinded trial participants; allocation, amount and medical records are unverified. Selected public replies, not a representative sample.

Source context — Viking Therapeutics: oral-trial participant reply: Anonymous, self-identified blinded trial participants; allocation, amount and medical records are unverified. Selected public replies, not a representative sample. Stock promotion accompanies report; no tablet amount or follow-up duration disclosed.

Source context — Viking VK2735 pipeline overview: Sponsor summary with commercial interest; headline tolerability language does not establish safety or approval.

Source context — VENTURE weekly injection trial poster: Sponsor-hosted poster text reviewed; screenshot request returned only a reference, not an inspectable image. No full journal-body access claimed. Group data, not personal amounts.

Source context — Viking VENTURE-Oral results, August 2025: Sponsor topline; group outcomes and adverse events do not predict individual experience. Higher-arm titration differs.

Half-life, onset & duration

Felt onset	Separate injection participants describe fullness around ten hours, day two or day three. Quiet first weeks and slower changes also occur; this is not a validated onset range.
Felt duration	Some describe stronger suppression on days 1–4 or 1–5 and more hunger later. One skipped-week account retained eating control into week two; repeated use cannot establish a single-dose two-week benefit.
Half-life	The Phase 1 single-injection measurement circulated online is 170–250 hours. A rounded 9–10-day reply is not a new measurement, an oral value or an appetite-duration clock.
Blood peak	The Phase 1 sponsor disclosure gives 75–90 hours after single subcutaneous doses. Blood peak and earlier subjective fullness are separate observations.

Notes

About 10 hours, day 2, or day 3 in separate injection accounts. Separate participants describe fullness after 10 hours, change on day 2, and reduced snack interest by day 3. These are different observations, not a validated onset range. Anyone on the Vanquish 1 trial? (Community discussion · Accessed 2026-09-30) · BMI at 24 (Personal report · Accessed 2026-09-30)

Stronger suppression during days 1–4 or 1–5; more hunger later. Two participants describe this weekly pattern. One who skipped a week noticed more appetite near the end of week two while retaining control of eating. This is subjective timing during repeated use, not proof that one dose works for two weeks. At what point is BMI too low? (Community discussion · Accessed 2026-09-30) · VK2735 maintenance trial results this month. Will monthly shot work? (Community discussion · Accessed 2026-09-30)

170–250 hours is a trial-derived number circulated on Reddit. This reposted Phase 1 single-injection measurement describes drug concentration, not appetite suppression. Another reply rounds it to 9–10 days without its own measurement. Neither supplies an oral value or personal clearance clock. Community repost of Viking Phase 1 results (Secondhand community claim · Accessed 2026-09-30) · At what point is BMI too low? (Community discussion · Accessed 2026-09-30)

Plasma peak is separate from felt onset. The Phase 1 sponsor disclosure reports a 75–90-hour peak after single SubQ doses. That measurement does not contradict earlier subjective changes or provide an oral timing value. Viking Phase 1 results, March 2023 (Official context · Accessed 2026-09-30)

Source context — Anyone on the Vanquish 1 trial? / BMI at 24 / 4th Dose: Anonymous, self-identified blinded trial participants; allocation, amount and medical records are unverified. Selected public replies, not a representative sample.

Source context — At what point is BMI too low?: Anonymous, self-identified blinded trial participants; allocation, amount and medical records are unverified. Selected public replies, not a representative sample. Replies include unsupported low-BMI safety assurances; these are rejected.

Source context — VK2735 maintenance trial results this month. Will monthly shot work?: Anonymous, self-identified blinded trial participants; allocation, amount and medical records are unverified. Selected public replies, not a representative sample. Participant experience is separate from opening predictions and trial readout.

Source context — Community repost of Viking Phase 1 results: Reposted clinical measurement, not independently measured community kinetics or oral kinetics. Promotional investor setting.

Source context — Viking Phase 1 results, March 2023: Early sponsor disclosure, not complete participant-level PK; no oral value inferred.

Cycles people discuss

Continuing treatment	Participants describe months to roughly a year, reductions near goal weight and post-trial worries. One restarted two steps lower after a medical pause; that is an individual history, not a universal restart rule.
After a pause	One participant reports pronounced hunger and 12 lb regained during a four-week pause for gallbladder surgery. Surgery and recovery complicate that account; no agreed on/off maintenance calendar emerges.

Notes

Months of continuing treatment, rather than a short on/off cycle. Participants discuss roughly a year of treatment, reduced amounts near goal weight and post-trial worries. One restarted two dose steps lower after a medical pause; this is not a universal restart rule. VK2735 maintenance trial results this month. Will monthly shot work? (Community discussion · Accessed 2026-09-30) · Gallbladder removal and what happened after pausing injections (Personal report · Accessed 2026-09-30)

Stopping can bring a different experience. After a four-week pause for gallbladder surgery, another participant reported pronounced hunger and 12 lb regained. Surgery and recovery complicate that account; it does not erase other people’s longer residual appetite control. Gallbladder removal and what happened after pausing injections (Personal report · Accessed 2026-09-30)

Less-frequent maintenance attracts hope and caution. A September discussion welcomes monthly and every-other-week results while emphasizing small groups and only 12 weeks of maintenance follow-up. Participants’ fear of regain and access after the trial remains understandable; these results do not establish permanent maintenance. Maintenance data are out: what changed? (Community opinion · Accessed 2026-09-30) · VK2735 maintenance trial results this month. Will monthly shot work? (Community discussion · Accessed 2026-09-30)

Source context — Gallbladder removal and what happened after pausing injections: Anonymous, self-identified blinded trial participants; allocation, amount and medical records are unverified. Selected public replies, not a representative sample. Surgery, illness and diet confound weight change. Same author as restart report, not an independent case.

Source context — Maintenance data are out: what changed?: Investor interpretation of sponsor data, not participant testimony or long-term maintenance proof.

Stacks

Comparisons rather than combinations	Tirzepatide, semaglutide, retatrutide and orforglipron are discussed mainly as alternatives. These trial-centered records do not establish a specific simultaneous drug stack.
Protein and training	Participants discuss remembering meals, protein and workouts to preserve muscle. Those habits accompany the reports without establishing a muscle-protection result.

Notes

A trial drug, with comparisons rather than established stacks. People compare it with Tirzepatide, Semaglutide, Retatrutide and Orforglipron. Shared targets do not support substitution or combining them. These accounts mainly concern supervised trials. Anyone on the Vanquish 1 trial? (Community discussion · Accessed 2026-09-30)

Comparisons, not co-stacks: Discussion sits next to tirzepatide, semaglutide, retatrutide, CagriSema, amycretin, survodutide, orforglipron — usually as alternatives, not simultaneous injectables. [community]

Preserving muscle becomes a practical goal. A participant who resumed workouts emphasized protein and remembering meals; another at week 37 focused on keeping muscle. These extend the older training discussion without establishing a muscle-protection result. 4th Dose (Community discussion · Accessed 2026-09-30) · 36 week shot (Community discussion · Accessed 2026-09-30)

Watch for

Eating and bodily symptoms	Reports include fatigue, skin sensitivity, low blood pressure, high heart rate and forgetting meals. Continued loss despite a reduced amount also raises nutrition concerns.
Serious experiences and product identity	One participant reports gallstones, surgery and severe diarrhea after restarting. Trial supply differs from unverified products bearing the name; long-term risks and interactions are not settled by welcome weight loss.

Notes

Appetite suppression can make eating difficult. Reports include forgetting meals, lethargy, skin sensitivity, low blood pressure and high heart rate. Other participants describe manageable appetite with few side effects. One person’s easy course does not establish that adverse symptoms will settle for everyone. Has anyone considered dropping out of the study? (Community discussion · Accessed 2026-09-30) · Early participants? Just had my 11th injection and the increase to 7.5 (Community discussion · Accessed 2026-09-30)

Severe symptoms occurred alongside weight loss. One participant reported gallstones and surgery, then five days of diarrhea and hair loss after restarting injections. Another kept losing after a dose reduction and worried about becoming too thin. These are reasons for clinical assessment, not proof of a single cause. Update #2: post-gallbladder removal (Personal report · Accessed 2026-09-30) · At what point is BMI too low? (Community discussion · Accessed 2026-09-30)

Trial supply and a product bearing the name are different. The original discussion distinguishes clinical VK2735 from unverified powders, vials or capsules. Trial results cannot authenticate those products. Long-term risk, nutrition and interactions remain relevant even when weight loss is welcome.

Source context — Has anyone considered dropping out of the study?: Anonymous, self-identified blinded trial participants; allocation, amount and medical records are unverified. Selected public replies, not a representative sample. Users' expectations that side effects will disappear are not established.

Source context — Early participants? Just had my 11th injection and the increase to 7.5: Anonymous, self-identified blinded trial participants; allocation, amount and medical records are unverified. Selected public replies, not a representative sample.

Source context — Update #2: post-gallbladder removal: Anonymous, self-identified blinded trial participants; allocation, amount and medical records are unverified. Selected public replies, not a representative sample. Same author as pause report; causal assertion is the user's, not verified diagnosis.

Full notes

What VK2735 is

One peptide, two formulations. GLP-1 and GIP are gut-hormone signals involved in appetite and blood-sugar regulation. VK2735 activates both receptors. Injections and clinical tablets contain the same molecule, but absorption differs; equal milligrams do not mean equivalent exposure. Official context Community
A trial drug, with comparisons rather than established stacks. People compare it with Tirzepatide, Semaglutide, Retatrutide and Orforglipron. Shared targets do not support substitution or combining them. These accounts mainly concern supervised trials. Community Reddit · r/VK2735

What participants hope for and report

Less food noise and easier fullness. Participants describe losing interest in sweets or stopping halfway through old portions. A fourth-dose account reported 13 lb lost and fewer dessert thoughts, alongside resumed exercise. Reddit · r/VK2735 Reddit · r/VK2735
Progress can slow without disappearing. At week 36, one poster reported 23% weight loss but six weeks of stable weight. Another described a month without scale loss followed by further progress. Those stories answer what a plateau feels like; they cannot forecast anyone else’s trajectory. Reddit · r/VK2735

Doses people discuss

Weekly SubQ: 7.5, 12.5 or 17.5 mg target-arm talk. SubQ means beneath the skin. Participants list these possible trial targets but often do not know their assignment. Another author describes a presumed increase to 7.5 mg at the eleventh injection. These are per-injection trial amounts discussed by users, not confirmed personal dose ladders. Reddit · r/VK2735 Reddit · r/VK2735 Reddit · r/VK2735
Oral: no dependable self-reported dose band here. An oral-trial commenter reports good tolerability and 22 lb lost without giving tablet strength or timing. Daily oral trial milligrams and weekly injection milligrams cannot be converted one-for-one; neither establishes the contents of a nonclinical product. Personal report Community

Half-life

170–250 hours is a trial-derived number circulated on Reddit. This reposted Phase 1 single-injection measurement describes drug concentration, not appetite suppression. Another reply rounds it to 9–10 days without its own measurement. Neither supplies an oral value or personal clearance clock. Reddit · r/Optionmillionaires Reddit · r/VK2735

Onset: when a change is noticed

About 10 hours, day 2, or day 3 in separate injection accounts. Separate participants describe fullness after 10 hours, change on day 2, and reduced snack interest by day 3. These are different observations, not a validated onset range. Reddit · r/VK2735 Personal report
A quiet first week or slower change also appears. One poster initially suspected placebo, then noticed less craving. Another approaching the ninth injection reported fullness and occasional nausea but under 10 lb lost. Blinding prevents calling a slow or absent response a confirmed VK2735 failure. Reddit · r/VK2735 Reddit · r/VK2735

Duration: appetite and weight changes

Stronger suppression during days 1–4 or 1–5; more hunger later. Two participants describe this weekly pattern. One who skipped a week noticed more appetite near the end of week two while retaining control of eating. This is subjective timing during repeated use, not proof that one dose works for two weeks. Reddit · r/VK2735 Reddit · r/VK2735PHASE3
Stopping can bring a different experience. After a four-week pause for gallbladder surgery, another participant reported pronounced hunger and 12 lb regained. Surgery and recovery complicate that account; it does not erase other people’s longer residual appetite control. Personal report

Cycles and maintenance

Months of continuing treatment, rather than a short on/off cycle. Participants discuss roughly a year of treatment, reduced amounts near goal weight and post-trial worries. One restarted two dose steps lower after a medical pause; this is not a universal restart rule. Reddit · r/VK2735PHASE3 Personal report Community

Good to know

Appetite suppression can make eating difficult. Reports include forgetting meals, lethargy, skin sensitivity, low blood pressure and high heart rate. Other participants describe manageable appetite with few side effects. One person’s easy course does not establish that adverse symptoms will settle for everyone. Reddit · r/VK2735 Reddit · r/VK2735
Severe symptoms occurred alongside weight loss. One participant reported gallstones and surgery, then five days of diarrhea and hair loss after restarting injections. Another kept losing after a dose reduction and worried about becoming too thin. These are reasons for clinical assessment, not proof of a single cause. Personal report Reddit · r/VK2735
Trial supply and a product bearing the name are different. The original discussion distinguishes clinical VK2735 from unverified powders, vials or capsules. Trial results cannot authenticate those products. Long-term risk, nutrition and interactions remain relevant even when weight loss is welcome. Community

From community discussion

Preserving muscle becomes a practical goal. A participant who resumed workouts emphasized protein and remembering meals; another at week 37 focused on keeping muscle. These extend the older training discussion without establishing a muscle-protection result. Reddit · r/VK2735 Reddit · r/VK2735 Community
Mood reports include improvement and no change. Replies describe unchanged mood, no anhedonia, or feeling more capable. One person explicitly wonders whether feeling better comes from the drug or relief after weight loss. The thread’s receptor-based explanation is speculation. Reddit · r/VK2735
Oral convenience does not settle tolerability. The positive oral-trial report sits alongside debate about vomiting and dropout. A separate thread promotes a weekly pill, but completed oral Phase 2 dosing was daily. Needle avoidance is a real appeal; a post about convenience is not exposure evidence. Personal report Reddit · r/GLP1ResearchTalk Official context
Less-frequent maintenance attracts hope and caution. A September discussion welcomes monthly and every-other-week results while emphasizing small groups and only 12 weeks of maintenance follow-up. Participants’ fear of regain and access after the trial remains understandable; these results do not establish permanent maintenance. Reddit · r/biotech_stocks Reddit · r/VK2735PHASE3

Separately identified trial context

Injectable Phase 2: 2.5, 5, 10 or 15 mg once weekly for 13 weeks. Viking reports up to 14.7% mean weight loss from baseline. Nausea, vomiting, constipation and diarrhea occurred, with a drug-related serious dehydration event. Group averages do not verify a forum user’s assignment. Official context Official context
Oral Phase 2: 15, 30, 60, 90 or 120 mg daily for 13 weeks. Top-arm mean loss was 12.2%; vomiting occurred in 35% of the 90 and 120 mg groups, and 38% in the 120 mg group stopped treatment early. These are distinct trial outcomes, not community rates. Official context
September 2026 maintenance results. September 22 topline data followed 21 weeks of injections with 12 weeks of less-frequent treatment. Combined every-other-week groups retained 90% of prior loss; combined monthly groups retained 85%, versus 61% on placebo. Monthly meant every four weeks. Oral maintenance remained a future study part. Official context
Plasma peak is separate from felt onset. The Phase 1 sponsor disclosure reports a 75–90-hour peak after single SubQ doses. That measurement does not contradict earlier subjective changes or provide an oral timing value. Official context